CAR-T cell consultation

Management: PD Dr. med. Christian Schultze-Florey

Indications: For adult patients (according to current prescribing information) with relapsed or refractory

• diffuse large B-cell lymphoma (DLBCL), highly malignant B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL)
  • (relapse within 12 months after completion of first-line chemoimmunotherapy or refractory to this therapy; relapse after two or more lines of systemic therapy)
• follicular lymphoma
  • (grade 3B: recurrence within 12 months after completion of first-line chemoimmunotherapy or refractory to this therapy; recurrence after two or more lines of systemic therapy)
• Mantle cell lymphoma
  • (after two or more lines of systemic therapy that include a Bruton's tyrosine kinase (BTK) inhibitor)
• B-ALL
  • (up to 25 years: relapse after transplantation, or second or later relapse; from 26 years: relapsed or refractory B-cell precursor ALL)
• Multiple myeloma
  • (disease progression during at least one therapy with immunomodulator and a proteasome inhibitor incl. refractory to lenalidomide or disease progression during at least two previous therapies, including immunomodulator, proteasome inhibitor and an anti-CD38 antibody)